Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:47 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,788 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intervention 2 - Sham Treatment Clear all
Not listed Not applicable Interventional

Additional Dietary Large Neutral Amino Acids (LNAA) for Improved Symptoms in Adult Classical Phenylktonuria (PKU)

NCT05174559
View directory record Official record
Conditions
Phenylketonurias
Interventions
PreKUnil® LNAA Medical Food for PKU
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Nov 3, 2026, 7:47 AM EST
Recruiting Phase 3 Interventional

Vitamin D for Prostate Endocrine Therapy

NCT05838716
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, D Vitamin, Dual X-ray Absorptiometry, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
51
States / cities
Newark, Delaware • Danville, Illinois • Decatur, Illinois + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Nov 3, 2026, 7:47 AM EST
Recruiting Phase 2 Interventional

A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)

NCT07704840
View directory record Official record
Conditions
Post-Stroke Spasticity
Interventions
Administration of BMS-986368, Placebo
Drug
Lead sponsor
Alberto Esquenazi
Other
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

NCT01232803
View directory record Official record
Conditions
Rectal Microbicides
Interventions
Tenofovir 1% gel, 2% N-9 gel, HEC Placebo gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Nov 3, 2026, 7:47 AM EST
Terminated Phase 2 Interventional Results available

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

NCT03018288
View directory record Official record
Conditions
Glioblastoma
Interventions
Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 4 Interventional Results available

Corticosteroid Pulse After Ablation

NCT00807586
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Solumedrol, Placebo
Drug
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Nov 3, 2026, 7:47 AM EST
Completed Not applicable Interventional

Remote Ischemic Conditioning, Bimanual Skill Learning, and Corticospinal Excitability

NCT05355883
View directory record Official record
Conditions
Unilateral Cerebral Palsy, Hemiplegic Cerebral Palsy, Remote Ischemic Conditioning
Interventions
Remote Ischemic Conditioning (RIC), Sham conditioning, Hand Arm Bimanual Intensive Therapy (HABIT), Bimanual Cup Stacking Training, Balance training
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
6 Years to 16 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

NCT05089656
View directory record Official record
Conditions
Type 2 Spinal Muscular Atrophy
Interventions
OAV101, Sham control
Genetic · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Farmington, Connecticut • Chicago, Illinois • Strasburg, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Nov 3, 2026, 7:47 AM EST
Terminated Phase 3 Interventional Results available

Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02587351
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Metoprolol succinate, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 84 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 2Phase 3 Interventional Results available

Early Levothyroxine Post Radioactive Iodine

NCT01950260
View directory record Official record
Conditions
Graves' Disease
Interventions
Levothyroxine, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Nov 3, 2026, 7:47 AM EST
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

NCT07214974
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions
Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator
Behavioral · Device · Biological + 1 more
Lead sponsor
Noah Tech, Corp.
Industry
Eligibility
55 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palisades Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 2 Interventional

Rifamycin in Minimal Hepatic Encephalopathy

NCT04082780
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
Rifamycin SV MMX, Placebo
Drug · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 3, 2026, 7:47 AM EST
Not yet recruiting Not applicable Interventional

Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)

NCT07527273
View directory record Official record
Conditions
Aging, Depression, Cognitive Symptoms
Interventions
Depression Cognitive Training, Non-Specific Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation)
Behavioral · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 7:47 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

One-4-ALL Initiative

NCT05454969
View directory record Official record
Conditions
Literacy, Burden, Caregiver, Health Care Utilization
Interventions
One-4-ALL Initiative, Control
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Nov 3, 2026, 7:47 AM EST
Terminated Phase 4 Interventional

Functional Vision in TBI

NCT01214070
View directory record Official record
Conditions
Brain Injuries, Visually Impaired Persons
Interventions
Vision Restoration Therapy, NVT Eye Scanning Therapy, Eccentric Viewing Training, Sham
Other · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
20 Years to 79 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Nov 3, 2026, 7:47 AM EST
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.

NCT04049266
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
59
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Nov 3, 2026, 7:47 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency

NCT05877560
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Anodal-Transcranial Direct Current Stimulation, Office-Based Vergence/Accommodative Therapy, Sham Transcranial Direct Current Stimulation
Device · Behavioral
Lead sponsor
Midwestern University
Other
Eligibility
18 Years to 40 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Downers Grove, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Nov 3, 2026, 7:47 AM EST
Completed Early Phase 1 Interventional Results available

A Mind Body Intervention to Reduce Symptoms Among People Aging With HIV

NCT03840525
View directory record Official record
Conditions
Mental Health, Physical Health
Interventions
The Qigong Intervention, Sham Qigong
Behavioral
Lead sponsor
Florida International University
Other
Eligibility
50 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Nov 3, 2026, 7:47 AM EST
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 2 Interventional

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

NCT04918719
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Acetylcysteine, Dextrose in Water
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Nov 3, 2026, 7:47 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes

NCT05907850
View directory record Official record
Conditions
Muscle Soreness
Interventions
Riboflavin, Placebo
Drug
Lead sponsor
Steven Moore
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Nov 3, 2026, 7:47 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

NCT03522506
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Nov 3, 2026, 7:47 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Wearable Focused Ultrasound Stimulation for Peripheral Nerve Pain Management

NCT07160049
View directory record Official record
Conditions
Pain Management, Peripheral Neuropathic Pain
Interventions
Cold Pressor Task - Upper Limb, Algometry Pain Tests in the Upper Limb, Algometry Pain Tests in the Lower Limb
Device
Lead sponsor
Evan (Huiliang) Wang
Other
Eligibility
20 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 3, 2026, 7:47 AM EST